Pacific Biosciences Of California (PACB) Work In Process (2011 - 2026)

Pacific Biosciences Of California's Work In Process history runs 16 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• On a quarterly basis, Work In Process rose 9.77% year-over-year to $27.3 million in Q1 2026; TTM through Mar 2026 was $27.3 million, a 9.77% increase from a year earlier, with the FY2025 full-year figure at $27.1 million, up 22.01% from the prior year.
• Work In Process advanced to $27.3 million in Q1 2026 per PACB's latest filing, from $27.1 million in the prior quarter.
• Across five years, Work In Process topped out at $27.9 million in Q3 2023 and bottomed at $9.2 million in Q1 2022.
• The 5-year median for Work In Process is $22.6 million (2023), against an average of $21.7 million.
• Across the five-year window, Work In Process jumped 135.87% in 2023 and slumped 34.4% in 2024, its largest moves.
• Year by year, Work In Process stood at $14.1 million in 2022, then surged by 96.65% to $27.7 million in 2023, then declined by 19.82% to $22.2 million in 2024, then climbed by 22.01% to $27.1 million in 2025, then increased by 1.1% to $27.3 million in 2026.
• Per Business Quant, the three latest PACB Work In Process figures stand at $27.3 million (Q1 2026), $27.1 million (Q4 2025), and $25.2 million (Q3 2025).